/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Merus NV

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$95.98 0.0014(0.14%) MRUS at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 96.045
Highest Today 96.16
Today’s Open 96.08
Prev. Close 95.99
52 Week High 96.28
52 Week Low 33.19
Day’s Range: Low 96.045 High 96.16
52-Week Range: Low 33.19 High 96.28
1 day return -
1 Week return -0.02
1 month return +1.16
3 month return +45.12
6 month return +66.92
1 year return +111.55
3 year return +576.97
5 year return +442.18
10 year return -

Institutional Holdings

FMR Inc 9.90

Paradigm Biocapital Advisors LP 5.66

RTW INVESTMENTS, LLC 5.29

Wellington Management Company LLP 4.93

COMMODORE CAPITAL LP 4.66

Deerfield Management Co 4.48

venBio Select Advisor LLC 4.17

T. Rowe Price Associates, Inc. 2.99

Holocene Advisors, LP 2.94

Westfield Capital Management Company, L.P. 2.70

Franklin Resources Inc 2.43

Vanguard Health Care Inv 2.23

Polar Capital Holdings PLC 2.13

Woodline Partners LP 2.04

Federated Hermes Inc 2.02

Driehaus Capital Management LLC 1.81

Fidelity Select Health Care 1.53

Ameriprise Financial Inc 1.50

Cormorant Asset Management, LLC 1.48

AllianceBernstein L.P. 1.46

Rock Springs Capital Management LP 1.41

BlackRock Inc 1.39

HBM Healthcare Investments AG Ord 1.32

Polar Capital Healthcare Opports Inc 1.25

Federated Hermes Kaufmann Small Cap A 1.09

Federated Hermes Kaufmann Small Cap Grow 1.09

Strategic Advisers Fidelity US TtlStk 0.99

Fidelity Select Biotechnology 0.94

Federated Hermes Kaufmann Growth 0.91

Federated Hermes Kaufmann R 0.91

Fidelity Advisor Health Care I 0.86

Franklin Biotechnology Discv A(acc)USD 0.84

US Small-Cap Growth II Equity Comp 0.78

Pictet-Biotech P USD 0.77

Franklin US Small Cap Growth Equity 0.75

Fidelity Small Cap Growth 0.73

Columbia Cornerstone Growth 0.70

T. Rowe Price Health Sciences 0.70

Franklin Small Cap Growth Adv 0.69

Columbia Cornerstone Growth Inst 0.69

Market Status

Strong Buy: 13

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 7280.57 M

PB Ratio 9.4098

PE Ratio 0.0

Enterprise Value 6668.33 M

Total Assets 785.13 M

Volume 1553520

Company Financials

Annual Revenue FY23:45674000 45.7M, FY22:41586000 41.6M, FY21:49107000 49.1M, FY20:29943000 29.9M, FY19:31133000 31.1M

Annual Profit FY23:null 0.0M, FY22:29604000 29.6M, FY21:49107000 49.1M, FY20:29943000 29.9M, FY19:31133000 31.1M

Annual Net worth FY23:-176758000 -176.8M, FY22:-131194000 -131.2M, FY21:-66816000 -66.8M, FY20:-85513000 -85.5M, FY19:-55151000 -55.2M

Quarterly Revenue Q3/2025:10373548 10.4M, Q2/2025:7494972 7.5M, Q1/2025:24482858 24.5M, Q3/2024:11772000 11.8M, Q2/2024:7332000 7.3M

Quarterly Profit Q3/2025:9824561 9.8M, Q2/2025:-72248202 -72.2M, Q1/2025:-49568360 -49.6M, Q3/2024:11772000 11.8M, Q2/2024:7332000 7.3M

Quarterly Net worth Q3/2025:-81554020 -81.6M, Q2/2025:-134327082 -134.3M, Q1/2025:-89170918 -89.2M, Q3/2024:-99905000 -99.9M, Q2/2024:-50042000 -50.0M

Fund house & investment objective

Company Information Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Organisation Biotechnology

Employees 260

Industry Biotechnology

CEO Dr. Sven Ante Lundberg M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow